Rowan University

Rowan Digital Works
Stratford Campus Research Day

26th Annual Research Day

May 5th, 12:00 AM

A Case Report on Causes of COVID-19 Induced Psychosis and
Treatments
Jennifer Pires
Rowan University

Steven Sarner
Rowan University

Follow this and additional works at: https://rdw.rowan.edu/stratford_research_day
Part of the Amino Acids, Peptides, and Proteins Commons, Biological Phenomena, Cell Phenomena,
and Immunity Commons, Pathological Conditions, Signs and Symptoms Commons, Physiological
Processes Commons, and the Virus Diseases Commons

Let us know how access to this document benefits you - share your thoughts on our feedback
form.
Pires, Jennifer and Sarner, Steven, "A Case Report on Causes of COVID-19 Induced Psychosis and
Treatments" (2022). Stratford Campus Research Day. 7.
https://rdw.rowan.edu/stratford_research_day/2022/May5/7

This Poster is brought to you for free and open access by the Conferences, Events, and Symposia at Rowan Digital
Works. It has been accepted for inclusion in Stratford Campus Research Day by an authorized administrator of
Rowan Digital Works.

A case report on causes of COVID-19 induced psychosis and treatments
Jennifer Pires OMS III, Steven Sarner MD

Rowan University School of Osteopathic Medicine, 42 E Laurel Rd., Stratford NJ 08084

Background
•

•

•

•

•

COVID-19 is a viral infection that is caused by an RNA virus in a
subfamily of Coronaviridae named severe acute respiratory
syndrome (SARS-CoV-2). The family also includes severe acute
respiratory syndrome coronavirus (SARS-CoV) and middle east
respiratory syndrome coronavirus (MERS-CoV) which have
previously been shown to cause respiratory symptoms and
psychosis with immunoreactivity to IgG. 1-4
Hypothesis 1: Viruses can act on the brain and cause psychosis.
Herpes Simplex Virus triggers the formation of anti-NMDAR IgG1
antibodies which activate the NMDA receptor causing neural
excitability leading to neuropsychosis.5
Hypothesis 2: Psychosis may be caused by increased cytokine
factors including IL-1B, IL-6, TNF and CRP. These cytokines are
associated with inflammation and changes in mood, social
behavior and cognitive behavior.5
Hypothesis 3: Steroid induced psychosis is the most popular theory
currently. Long term synthetic steroids can disrupt the
hypothalamo-pituitary adrenal axis including the cortisol pathway
leading to mood disorders including depression, anxiety and
mania.6, 7
Hypothesis 4: The global pandemic is believed to have affected the
current mental state of people. The disease precautions such as
social distancing and school closings can contribute to increased
rates of depression, anxiety and increased substance use which
contribute to a person’s personal vulnerability to develop
psychosis.8,9
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Discussion

Patient is a 63-year-old caucasian female with a history of GERD and
•
hyperlipidemia. MS developed a non-productive cough, nasal congestion,
and general myalgia 12 days prior to hospitalization. She was referred for
monoclonal antibody treatment. When she arrived at the facility, she was
found to have a pulse ox in the mid-80’s associated with exertional
dyspnea.
ED work up included vital signs: BP: 107/51mmHg, Temperature 99F; Pulse •
80BPM, RR: 20/min, Exertional Pulse OX: 90% on RA, Resting Pulse OX: 95%
on RA. The chest x-ray showed bilateral patchy interstitial alveolar
opacities suggesting pneumonia secondary to COVID-19. EKG showed SR
75BPM with no acute changes. Other significant lab findings included: Ddimer: 1.5; CRP: 176; LDH of 524 and a positive COVID-19 PCR test.

Initial treatment included Decadron 6mg daily for 10 days, Vibramycin
100mg twice a day for 7 days and Eliquis 5mg twice a day. She did not
receive Remdesivir as she was outside the therapeutic window. She was
discharged after 1 day on observation with oxygen and the above
medications.
Five days after the patient was discharged, she returned to the ED via EMS
due to “erratic behavior” and tachycardia, 144BPM. The patient presented
with tangential, pressured speech, decreased sleep, decreased
concentration, irritability and delusions of grandiosity. ED staff discussed
the possibility of steroid induced neuropsychiatric symptoms, but she did
not improve with the cessation of steroids. Her respiratory symptoms had
improved at the time of this evaluation.

•

•

Case reports in Madrid suggested two timelines for COVID-19induced psychosis: subacute onset in which psychotic symptoms
lasted for less than one week and quick recovery where symptoms
lasted less than two weeks with the assistance of antipsychotics.
MS required longer treatment and the addition of a mood
stabilizer.10
Another case described a 36-year-old female with no personal or
family history who developed similar psychotic symptoms to MS,
but this patient developed them 4 days after respiratory symptoms
began and they resolved rapidly with an antipsychotic which she
discontinued on her own with no recurrence. This difference may
be attributed to their age difference.11
Another patient was a 54-year-old female who presented 3 weeks
after discharge for COVID treatment with neuropsychiatric
symptoms similar to MS. Both patients required a combination
therapy of a mood stabilizer and antipsychotic. However, this
patient has a personal and family history of psychotic disorders.12
As with most psychiatric conditions, the goal is symptom
management with a return to baseline mental status. Various
treatments have been discussed such as second-generation
antipsychotics, mood stabilizers, IVIG, cessation of steroids and
immunotherapies. However more research needs to be conducted
so patients can return to their baseline sooner and avoid readmissions. 5,13,14

Conclusion

She had CT scans and an MRI of her brain which revealed no acute
intracranial findings. She experienced 30 seconds of seizure like activity in Overall, MS’s prolonged symptoms and requirement of dual treatment
the MRI prompting an EEG which showed no epileptic activity. The seizures of antipsychotic and a mood stabilizer makes her case unique and
were attributed to 7 days of insomnia, but alcohol withdrawal could not be could help future patients have a shorter timeline of symptoms. It is
important to discuss the various causes of COVID-19 induced psychosis
ruled out. She started on Naltrexone and Quetiapine with minimal
to implement preventative measures. However, more importantly the
improvements prompting a voluntary admission to the psychiatric unit.
proper management of these patients needs to occur so they can return
After 8 days on the medical floor, the patient spent 11 days on the
to baseline sooner, and this area requires more research.
psychiatric floor. Her medication regime had to adjusted multiple times
due to lack of stabilization of psychosis and insomnia. She was finally
stabilized and discharged on Depakote 1250mg daily, Quetiapine 300mg
daily and Trazadone 100mg daily, with a diagnosis of bipolar affective
1. Umakanthan S et al. Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19). Postgrad Med J.
2020;96(1142):753-758.
disorder.
2. de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol.
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